Pooneh Rahimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pooneh Rahimi has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Vahid Iranpur Mobarakeh
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
5 shared publications Amir Sohrabi
Department of Molecular Medicine, School of Advanced Medical Technologies, Tehran University of Medical Sciences, Tehran, IR Iran
4 shared publications- Ehsan Mostafavi
National Reference laboratory for Plague, Tularemia and Q fever, Research Centre for Emerging and Reemerging infectious diseases, Pasteur Institute of Iran, Kabudar Ahang, Iran
4 shared publications Rouhollah Vahabpour
Medical Lab Technology Department, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 shared publicationsAkram Roohandeh
Pharmaceutical Science Branch, Islamic Azad University, Tehran, IR Iran
3 shared publicationsAzam Bolhassani
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
3 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 27 (1)
Association of IL-8 and IL-8R1 gene polymorphisms with COVID-19 mortality
Background: Host genetic factors contribute to the heterogeneity of clinical outcomes in Coronavirus Disease 2019 (COVID-19). Interleukin-8 (IL-8) and its receptor IL-8R1 (CXCR1) play key roles in inflammatory responses and cytokine-mediated tissue damage during severe SARS-CoV-2 infection. This study investigated the association of IL-8 rs4073 and rs2227306, as well as IL-8R1 rs2234671 polymorphisms, with COVID-19 mortality in an Iranian population. Methods: A total of 328 hospitalized COVID-19 patients, including 178 recovered and 150 deceased individuals, were enrolled. Genotyping of IL-8 rs4073, IL-8 rs2227306, and IL-8R1 rs2234671 polymorphisms was performed using polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), and selected samples were confirmed by Sanger sequencing. Genotype and allele frequencies were compared between groups, and logistic regression models were applied to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Multilocus genotype combination analysis was also conducted. Results: The IL-8R1 rs2234671 polymorphism showed a significant association with COVID-19 mortality. Carriers of the G allele exhibited an increased risk of death compared with CC homozygotes under codominant, dominant, overdominant, and log-additive inheritance models (all P < 0.05). The strongest association was observed under the dominant model (OR = 3.29, 95% CI = 1.55–6.99, P = 0.0014). In contrast, IL-8 rs4073 and rs2227306 polymorphisms showed no statistically significant associations with mortality when analyzed individually. Multilocus genotype combination analysis suggested that specific combinations involving IL-8R1 rs2234671 may influence clinical outcomes, although these findings require further validation. Conclusions: Our findings indicate that the IL-8R1 rs2234671 polymorphism is associated with COVID-19 mortality in the studied Iranian population, supporting the importance of IL-8/CXCR1-mediated inflammatory pathways in disease progression. Although individual IL-8 polymorphisms were not significantly associated with mortality, combined genetic effects may contribute to outcome variability. However, the proposed functional mechanisms remain to be experimentally validated. Larger multi-ethnic studies and functional investigations are needed to validate these associations and clarify their biological significance. Clinical trial number: Not applicable.
- 4 November 2026
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 27 (1)
Open AccessAssociation of IL-8 and IL-8R1 gene polymorphisms with COVID-19 mortality
Background: Host genetic factors contribute to the heterogeneity of clinical outcomes in Coronavirus Disease 2019 (COVID-19). Interleukin-8 (IL-8) and its receptor IL-8R1 (CXCR1) play key roles in inflammatory responses and cytokine-mediated tissue damage during severe SARS-CoV-2 infection. This study investigated the association of IL-8 rs4073 and rs2227306, as well as IL-8R1 rs2234671 polymorphisms, with COVID-19 mortality in an Iranian population. Methods: A total of 328 hospitalized COVID-19 patients, including 178 recovered and 150 deceased individuals, were enrolled. Genotyping of IL-8 rs4073, IL-8 rs2227306, and IL-8R1 rs2234671 polymorphisms was performed using polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP), and selected samples were confirmed by Sanger sequencing. Genotype and allele frequencies were compared between groups, and logistic regression models were applied to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Multilocus genotype combination analysis was also conducted. Results: The IL-8R1 rs2234671 polymorphism showed a significant association with COVID-19 mortality. Carriers of the G allele exhibited an increased risk of death compared with CC homozygotes under codominant, dominant, overdominant, and log-additive inheritance models (all P < 0.05). The strongest association was observed under the dominant model (OR = 3.29, 95% CI = 1.55–6.99, P = 0.0014). In contrast, IL-8 rs4073 and rs2227306 polymorphisms showed no statistically significant associations with mortality when analyzed individually. Multilocus genotype combination analysis suggested that specific combinations involving IL-8R1 rs2234671 may influence clinical outcomes, although these findings require further validation. Conclusions: Our findings indicate that the IL-8R1 rs2234671 polymorphism is associated with COVID-19 mortality in the studied Iranian population, supporting the importance of IL-8/CXCR1-mediated inflammatory pathways in disease progression. Although individual IL-8 polymorphisms were not significantly associated with mortality, combined genetic effects may contribute to outcome variability. However, the proposed functional mechanisms remain to be experimentally validated. Larger multi-ethnic studies and functional investigations are needed to validate these associations and clarify their biological significance. Clinical trial number: Not applicable.
- Open Access
- 13 July 2023
- Published by Taylor & Francis in Future Virology
- Vol. 18 (9) , 563-574
Expression of TRIM56 Gene in SARS-CoV-2 Variants and its Relationship with Progression of COVID-19
Aim: The present study aimed to determine a correlation between differential TRIM56 expression levels and severe infections of COVID-19 between the Alpha, Delta and Omicron BA.5 variants. Materials... Plain language summary Scientists looked at a protein called TRIM that helps fight viruses to see if a specific TRIM protein, TRIM56, was linked to how poorly people became with COVID-19. The study... Tweetable abstract #Tavakoli et al. discovered that the TRIM56 gene, which plays a crucial role in the body's immune response to viruses, is likely associated with severe COVID-19 infections.
- 13 July 2023
- Published by Taylor & Francis in Future Virology
- Vol. 18 (9) , 563-574
Open AccessExpression of TRIM56 Gene in SARS-CoV-2 Variants and its Relationship with Progression of COVID-19
Aim: The present study aimed to determine a correlation between differential TRIM56 expression levels and severe infections of COVID-19 between the Alpha, Delta and Omicron BA.5 variants. Materials... Plain language summary Scientists looked at a protein called TRIM that helps fight viruses to see if a specific TRIM protein, TRIM56, was linked to how poorly people became with COVID-19. The study... Tweetable abstract #Tavakoli et al. discovered that the TRIM56 gene, which plays a crucial role in the body's immune response to viruses, is likely associated with severe COVID-19 infections.
- Open Access
- 1 December 2022
- Published by Apex Publishing in Vaccine Research
- Vol. 9 (2) , 27-30
Isolation of Extracellular Vesicles of Akkermansia muciniphila as a Potential Therapeutic Platform
Introduction: Extracellular vesicles (EVs), an active biological compounds have significant roles in pathogenesis and intercellular interactions in both Gram-negative and Gram-positive bacteria.. A. muciniphila represents 3–5% of the gut microbiota community and is well-known in individuals with healthy gut through mucin degradation. Moreover, its abundance inversely correlates with body weight. ...
- 1 December 2022
- Published by Apex Publishing in Vaccine Research
- Vol. 9 (2) , 27-30
Open AccessIsolation of Extracellular Vesicles of Akkermansia muciniphila as a Potential Therapeutic Platform
Introduction: Extracellular vesicles (EVs), an active biological compounds have significant roles in pathogenesis and intercellular interactions in both Gram-negative and Gram-positive bacteria.. A. muciniphila represents 3–5% of the gut microbiota community and is well-known in individuals with healthy gut through mucin degradation. Moreover, its abundance inversely correlates with body weight. ...
- 1 May 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (5) , 1463-1469
Development of a T Cell-targeted siRNA Delivery System Against HIV-1 Using Modified Superparamagnetic Iron Oxide Nanoparticles: An In Vitro Study
- 1 May 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (5) , 1463-1469
Development of a T Cell-targeted siRNA Delivery System Against HIV-1 Using Modified Superparamagnetic Iron Oxide Nanoparticles: An In Vitro Study
- Open Access
- 10 June 2021
- Published by Institution of Engineering and Technology (IET) in IET Nanobiotechnology
- Vol. 15 (7) , 627-637
Lamivudine‐conjugated and efavirenz‐loaded G2 dendrimers: Novel anti‐retroviral nano drug delivery systems
Infection with human immunodeficiency virus (HIV)‐1 causes immunological disorders and death worldwide which needs to be further assisted by novel anti‐retroviral drug delivery systems. Consequently, finding newer anti‐retroviral pharmaceuticals by using biocompatible, biodegradable nanomaterials comprising a nanoparticle as core and a therapeutic agent is of high global interest. In this experiment, a second generation of a negatively charged nano‐biopolymer linear globular G2 dendrimer was carefully conjugated and loaded with well‐known anti‐HIV drugs lamivudine and efavirenz, respectively. They were characterised by a variety of analytical methods such as Zetasizer, Fourier‐transform infrared spectroscopy, elemental analysis and liquid chromatography‐mass spectroscopy. Additionally, conjugated lamivudine and loaded efazirenz with globular PEGylated G2 dendrimer were tested on an HEK293 T cell infected by single‐cycle replicable HIV‐1 virion and evaluated using XTT test and HIV‐1 P24 protein load. The results showed that lamivudine‐conjugated G2 significantly decreased retroviral activity without any cell toxicity. This effect was more or less observed by efavirenz‐loaded G2. These nano‐constructs are strongly suggested for further in vivo anti‐HIV assays.
- 10 June 2021
- Published by Institution of Engineering and Technology (IET) in IET Nanobiotechnology
- Vol. 15 (7) , 627-637
Open AccessLamivudine‐conjugated and efavirenz‐loaded G2 dendrimers: Novel anti‐retroviral nano drug delivery systems
Infection with human immunodeficiency virus (HIV)‐1 causes immunological disorders and death worldwide which needs to be further assisted by novel anti‐retroviral drug delivery systems. Consequently, finding newer anti‐retroviral pharmaceuticals by using biocompatible, biodegradable nanomaterials comprising a nanoparticle as core and a therapeutic agent is of high global interest. In this experiment, a second generation of a negatively charged nano‐biopolymer linear globular G2 dendrimer was carefully conjugated and loaded with well‐known anti‐HIV drugs lamivudine and efavirenz, respectively. They were characterised by a variety of analytical methods such as Zetasizer, Fourier‐transform infrared spectroscopy, elemental analysis and liquid chromatography‐mass spectroscopy. Additionally, conjugated lamivudine and loaded efazirenz with globular PEGylated G2 dendrimer were tested on an HEK293 T cell infected by single‐cycle replicable HIV‐1 virion and evaluated using XTT test and HIV‐1 P24 protein load. The results showed that lamivudine‐conjugated G2 significantly decreased retroviral activity without any cell toxicity. This effect was more or less observed by efavirenz‐loaded G2. These nano‐constructs are strongly suggested for further in vivo anti‐HIV assays.
- Open Access
- 28 January 2021
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 11
Prevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection
Background: Hepatitis C virus (HCV), non-structural 5A (NS5A), and non-structural 5B (NS5B) resistance-associated substitutions (RASs) are the main causes of failure to direct-acting antiviral agents (DAAs). NS5A and NS5B RASs can occur in patients with HCV infection naturally and before exposure to DAAs.Objectives: This study aimed to evaluate naturally-occurring NS5A and NS5B RASs in Iranian patients with HCV genotype 1a (HCV-1a) and -3a infections.Methods: In this cross-sectional study, viral RNA was extracted from serum specimens. NS5A and NS5B regions were amplified using RT-PCR followed by DNA sequencing. The results of nucleotide sequences were aligned against reference sequences of HCV-1a and -3a and the amino acid substitutions were analyzed using geno2pheno [hcv] web application.Results: Among 135 patients with hepatitis C, NS5A amino acid substitutions/RASs were identified in 26.4% and 15.9% of patients with HCV-1a and -3a infections, respectively. The identified amino acid substitutions/RASs in the NS5A region of patients with HCV-1a infection were M28T/V/I 11.1%, Q30R/H 4.2%, L31M 1.4%, and H58Y/P/C/D/Q/S/T 16.7%. Y93H substitution was not found in HCV-1a sequences. In patients with HCV-3a infection, NS5A amino acid substitutions/RASs were A30T/K 9.5%, L31F 1.6%, P58S/T/C 3.2%, Y93H 3.2%, and Y93N 3.2%. No resistance substitutions were identified in NS5B sequences from patients with HCV-1a and -3a infections.Conclusion: In this study, baseline amino acid substitutions/RASs were only identified in the NS5A region in Iranian patients with HCV-1a and -3a infections, and the prevalence of these amino acid substitutions/RASs were in accordance with similar studies. There were no RASs in the HCV-1a and -3a NS5B region.
- 28 January 2021
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 11
Open AccessPrevalence of Naturally-Occurring NS5A and NS5B Resistance-Associated Substitutions in Iranian Patients With Chronic Hepatitis C Infection
Background: Hepatitis C virus (HCV), non-structural 5A (NS5A), and non-structural 5B (NS5B) resistance-associated substitutions (RASs) are the main causes of failure to direct-acting antiviral agents (DAAs). NS5A and NS5B RASs can occur in patients with HCV infection naturally and before exposure to DAAs.Objectives: This study aimed to evaluate naturally-occurring NS5A and NS5B RASs in Iranian patients with HCV genotype 1a (HCV-1a) and -3a infections.Methods: In this cross-sectional study, viral RNA was extracted from serum specimens. NS5A and NS5B regions were amplified using RT-PCR followed by DNA sequencing. The results of nucleotide sequences were aligned against reference sequences of HCV-1a and -3a and the amino acid substitutions were analyzed using geno2pheno [hcv] web application.Results: Among 135 patients with hepatitis C, NS5A amino acid substitutions/RASs were identified in 26.4% and 15.9% of patients with HCV-1a and -3a infections, respectively. The identified amino acid substitutions/RASs in the NS5A region of patients with HCV-1a infection were M28T/V/I 11.1%, Q30R/H 4.2%, L31M 1.4%, and H58Y/P/C/D/Q/S/T 16.7%. Y93H substitution was not found in HCV-1a sequences. In patients with HCV-3a infection, NS5A amino acid substitutions/RASs were A30T/K 9.5%, L31F 1.6%, P58S/T/C 3.2%, Y93H 3.2%, and Y93N 3.2%. No resistance substitutions were identified in NS5B sequences from patients with HCV-1a and -3a infections.Conclusion: In this study, baseline amino acid substitutions/RASs were only identified in the NS5A region in Iranian patients with HCV-1a and -3a infections, and the prevalence of these amino acid substitutions/RASs were in accordance with similar studies. There were no RASs in the HCV-1a and -3a NS5B region.
- 1 January 2020
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 121 (10) , 733-741
Coronaviruses as the emerging threats for human health: should we be prepared for the future outbreaks of new coronaviruses?
Coronaviruses as the emerging threats for human health: should we be prepared for the future outbreaks of new coronaviruses?
- 1 January 2020
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 121 (10) , 733-741
Coronaviruses as the emerging threats for human health: should we be prepared for the future outbreaks of new coronaviruses?
Coronaviruses as the emerging threats for human health: should we be prepared for the future outbreaks of new coronaviruses?
- Open Access
- 1 June 2019
- Published by CMV Verlag in Vaccine Research
- Vol. 6 (1) , 43-49
Modification of SPION nanocarriers for siRNA delivery: A therapeutic strategy against HIV infection
Introduction: To date, while many studies have investigated antiviral agents or vaccines against HIV, success has been limited. In this field, mutagenesis of the viral genome often contributes to viral escape from the antiretroviral therapies and the emergence of HIV-1 strains resistant to the drugs. Therefore, developing alternative methods, including ...
- 1 June 2019
- Published by CMV Verlag in Vaccine Research
- Vol. 6 (1) , 43-49
Open AccessModification of SPION nanocarriers for siRNA delivery: A therapeutic strategy against HIV infection
Introduction: To date, while many studies have investigated antiviral agents or vaccines against HIV, success has been limited. In this field, mutagenesis of the viral genome often contributes to viral escape from the antiretroviral therapies and the emergence of HIV-1 strains resistant to the drugs. Therefore, developing alternative methods, including ...
- 29 May 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (11) , 20554-20565
Carboxymethyl dextran‐trimethyl chitosan coated superparamagnetic iron oxide nanoparticles: An effective siRNA delivery system for HIV‐1 Nef
Gene therapy, including small interfering RNA (siRNA) technology, is one of the leading strategies that help to improve the outcomes of the current therapeutic systems against HIV‐1 infection. The successful therapeutic application of siRNAs requires their safe and efficient delivery to specific cells. Here, we introduce a superparamagnetic iron oxide nanoparticle (SPION) for delivering siRNA against HIV‐1 nef (anti‐nef siRNA) into two cell lines, HEK293 and macrophage RAW 264.7. SPIONs were coated with trimethyl chitosan (TMC), and thereafter, different concentrations of SPION–TMC were coated with different ratios of a carboxymethyl dextran (CMD) to modify the physicochemical properties and improve the biological properties of the nanocarriers. The nanoparticles exhibited a spherical shape with an average size of 112 nm. The obtained results showed that the designed delivery route enhanced the uptake of siRNA into both HEK293 and RAW 264.7 cells compared with control groups. Moreover, CMD–TMC–SPIONs containing anti‐nef siRNA significantly reduced the expression of HIV‐1 nef in HEK293 stable cells. The modified siRNA‐loaded SPIONs also displayed no toxicity or apoptosis‐inducing effects on the cells. The CMD–TMC–SPIONs are suggested as potential nanocarriers for siRNA delivery in gene therapy of HIV‐1 infection.
- 29 May 2019
- Published by Wiley in Journal of Cellular Physiology
- Vol. 234 (11) , 20554-20565
Carboxymethyl dextran‐trimethyl chitosan coated superparamagnetic iron oxide nanoparticles: An effective siRNA delivery system for HIV‐1 Nef
Gene therapy, including small interfering RNA (siRNA) technology, is one of the leading strategies that help to improve the outcomes of the current therapeutic systems against HIV‐1 infection. The successful therapeutic application of siRNAs requires their safe and efficient delivery to specific cells. Here, we introduce a superparamagnetic iron oxide nanoparticle (SPION) for delivering siRNA against HIV‐1 nef (anti‐nef siRNA) into two cell lines, HEK293 and macrophage RAW 264.7. SPIONs were coated with trimethyl chitosan (TMC), and thereafter, different concentrations of SPION–TMC were coated with different ratios of a carboxymethyl dextran (CMD) to modify the physicochemical properties and improve the biological properties of the nanocarriers. The nanoparticles exhibited a spherical shape with an average size of 112 nm. The obtained results showed that the designed delivery route enhanced the uptake of siRNA into both HEK293 and RAW 264.7 cells compared with control groups. Moreover, CMD–TMC–SPIONs containing anti‐nef siRNA significantly reduced the expression of HIV‐1 nef in HEK293 stable cells. The modified siRNA‐loaded SPIONs also displayed no toxicity or apoptosis‐inducing effects on the cells. The CMD–TMC–SPIONs are suggested as potential nanocarriers for siRNA delivery in gene therapy of HIV‐1 infection.